Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: The Summer’s Most Talked About Sectors

The summer trading season is well underway as we celebrate a holiday here in Canada and this weekend in the US. Even on days that the markets were closed, the Bullboards on Stockhouse are wide open and busy with lively discussions on some of the biggest (and smallest) sto...
Stockhouse Editorial | June 30, 2021 |

Shaping the Future of Medicine by Delivering Regenerative Medicines

(Click image to play video) Envision a chest pain that feels like the most severe form of heartburn you ever experienced before. This is one of the main symptoms of ischemia – a disease which millions of people around the globe live with every day. Treati...
Dave Jackson | December 8, 2020 |

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...
Streetwise Reports | January 29, 2020 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

Syros Pharmaceuticals' shares rose 20% today after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 m...
Streetwise Reports | December 19, 2019 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Shaping the Future of Regenerative Medicine Today

(Click image to play video) Hemostemix Inc. ( TSX-V: HEM , OTC: HMTXF , Forum ) is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The Company’...
Dave Jackson | February 10, 2021 |

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ) , which focuse...
Streetwise Reports | May 6, 2020 |

Help 9 cent GEN.T save lives with cancer screening

Friday, March 4, 2016 | www.tickertrax.com | Help 9 Cent GEN.T Save Lives with Cancer Screening By Danny Deadlock, TickerTrax Note : I have been working on this report all day (s...
Danny Deadlock | March 4, 2016 |
1 2 3 4 5 6 7 8 9 10 ...